OVERVIEW

Clinical Consultations™: Targeting Nonalcoholic steatohepatitis (NASH): Expert Perspectives on Evolving Treatment Strategies is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 13, 2019
Expiration Date: November 13, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour(s).

Activity Overview:
Nonalcoholic steatohepatitis (NASH) is a severe type of fatty liver disease characterized by the accumulation of fat in the liver with inflammation and ballooning, with or without fibrosis and absent of significant alcohol consumption. The inflammation can progress to cirrhosis, portal hypertension, liver cancer, and eventual liver failure. NASH is projected to become the leading indication for liver transplant in the very near future. Fueled by the obesity epidemic and increasing prevalence of type 2 diabetes, NASH is considered the hepatic expression of metabolic syndrome. Because of low awareness of patients at risk of disease progression, the development of NASH is frequently not detected until cirrhosis is established. Current treatment consists of lifestyle interventions.

During this Clinical Consultations™, 2 expert faculty will review risk factors for fatty liver disease and the diagnostic tools used to determine which patients are at risk of disease progression. They will then discuss the latest evidence on novel compounds in clinical trials and conclude with practical application of points discussed through case presentations.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Apply a case-based approach to clinical assessment of NASH, including appropriate screening, diagnostic evaluation, and treatment
• Identify patients with nonalcoholic fatty liver disease (NAFLD) at increased risk of the development of NASH and those with NASH at risk of progression to advanced fibrosis
• Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
• Evaluate clinical trial data, mechanisms of action, and efficacy of emerging therapeutic agents targeting NASH